R. Kokko

2.6k total citations
22 papers, 836 citations indexed

About

R. Kokko is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, R. Kokko has authored 22 papers receiving a total of 836 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 18 papers in Cancer Research and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in R. Kokko's work include Breast Cancer Treatment Studies (18 papers), Cancer Treatment and Pharmacology (14 papers) and Advanced Breast Cancer Therapies (7 papers). R. Kokko is often cited by papers focused on Breast Cancer Treatment Studies (18 papers), Cancer Treatment and Pharmacology (14 papers) and Advanced Breast Cancer Therapies (7 papers). R. Kokko collaborates with scholars based in Finland and Sweden. R. Kokko's co-authors include Matti Hakama, K Holli, Vesa Kataja, Heikki Joensuu, Petri Bono, Päivi Auvinen, Pirkko‐Liisa Kellokumpu‐Lehtinen, R. Asola, Mika Leinonen and Leena Helle and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

R. Kokko

22 papers receiving 805 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Kokko Finland	12	650	410	247	163	107	22	836
Hannah Douthwaite Spain	6	717 1.1×	428 1.0×	262 1.1×	190 1.2×	78 0.7×	8	835
Svjetlana Mohrmann Germany	16	588 0.9×	441 1.1×	222 0.9×	236 1.4×	160 1.5×	63	1.1k
Massimo Rinaldo Italy	15	307 0.5×	299 0.7×	160 0.6×	104 0.6×	147 1.4×	29	690
Dieter Lampe Germany	14	412 0.6×	550 1.3×	333 1.3×	75 0.5×	425 4.0×	32	1.1k
Mette S. van Ramshorst Netherlands	11	426 0.7×	384 0.9×	147 0.6×	102 0.6×	92 0.9×	20	586
P. Chérel France	15	329 0.5×	345 0.8×	243 1.0×	164 1.0×	285 2.7×	39	816
Jean-François Boileau Canada	4	722 1.1×	440 1.1×	322 1.3×	182 1.1×	91 0.9×	5	856
R. Asola Finland	9	522 0.8×	281 0.7×	198 0.8×	215 1.3×	39 0.4×	16	697
Mikhail Byakhow Spain	2	875 1.3×	624 1.5×	309 1.3×	155 1.0×	125 1.2×	2	1.0k
N. Al-Sakaff Switzerland	11	901 1.4×	320 0.8×	338 1.4×	357 2.2×	60 0.6×	27	1.2k

Countries citing papers authored by R. Kokko

Since Specialization

Citations

This map shows the geographic impact of R. Kokko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Kokko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Kokko more than expected).

Fields of papers citing papers by R. Kokko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Kokko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Kokko. The network helps show where R. Kokko may publish in the future.

Co-authorship network of co-authors of R. Kokko

This figure shows the co-authorship network connecting the top 25 collaborators of R. Kokko. A scholar is included among the top collaborators of R. Kokko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Kokko. R. Kokko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Joensuu, Heikki, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen, et al.. (2017). Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer. JAMA Oncology. 3(6). 793–793. 57 indexed citations

Joensuu, Heikki, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen, et al.. (2016). Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial.. Journal of Clinical Oncology. 34(15_suppl). 1001–1001. 9 indexed citations

Joensuu, Heikki, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen, et al.. (2013). Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica. 53(2). 186–194. 22 indexed citations

Kellokumpu‐Lehtinen, Pirkko, R. Asola, Liisa Elomaa, et al.. (2013). Weekly paclitaxel--an effective treatment for advanced breast cancer.. PubMed. 33(6). 2623–7. 20 indexed citations

Joensuu, Heikki, Jeff Sperinde, M. Leinonen, et al.. (2011). Very high quantitative tumor HER2 content and outcome in early breast cancer. Annals of Oncology. 22(9). 2007–2013. 20 indexed citations

Joensuu, Heikki, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen, et al.. (2011). Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial. Journal of Clinical Oncology. 30(1). 11–18. 76 indexed citations

Lindman, Henrik, Riikka Huovinen, Arja Jukkola‐Vuorinen, et al.. (2010). Abstract PD01-02: Integration of Capecitabine into Anthracycline-and Taxane-Based Adjuvant Therapy for Triple-Negative Early Breast Cancer: Final Subgroup Analysis of the FinXX Study. Cancer Research. 70(24_Supplement). PD01–2. 4 indexed citations

Joensuu, Heikki, Pirkko Kellokumpu‐Lehtinen, Riikka Huovinen, et al.. (2010). Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): Efficacy in patients with triple-negative breast cancer (BC).. Journal of Clinical Oncology. 28(15_suppl). 531–531. 2 indexed citations

Joensuu, Heikki, Liisa Sailas, Tuomo Alanko, et al.. (2009). Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial. Annals of Oncology. 21(5). 968–973. 19 indexed citations

10.

Joensuu, Heikki, Peter Bono, Vesa Kataja, et al.. (2009). S24 Update of the FINHER trial based on 5 years of follow-up. The Breast. 18. S10–S10. 5 indexed citations

11.

Joensuu, Heikki, Pirkko Kellokumpu‐Lehtinen, Riikka Huovinen, et al.. (2009). Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) → 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial.. Cancer Research. 69(2_Supplement). 82–82. 8 indexed citations

12.

Joensuu, Heikki, Petri Bono, Vesa Kataja, et al.. (2009). Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial. Journal of Clinical Oncology. 27(34). 5685–5692. 326 indexed citations

13.

Joensuu, Heikki, Akseli Hemminki, Riikka Huovinen, et al.. (2007). The FinXX trial: Safety results in 600 patients (pts) randomized to either docetaxel (T) followed by cyclophosphamide (C) + epirubicin (E) + 5-FU (F) (CEF) or T + capecitabine (X) followed by CEX as adjuvant therapy for early breast cancer (BC). Journal of Clinical Oncology. 25(18_suppl). 11035–11035. 3 indexed citations

14.

Kokko, R., Matti Hakama, & K Holli. (2005). Follow-up Cost of Breast Cancer Patients with Localized Disease After Primary Treatment: a Randomized Trial. Breast Cancer Research and Treatment. 93(3). 255–260. 58 indexed citations

15.

Kokko, R., Matti Hakama, & K Holli. (2003). Role of Chest X-ray in Diagnosis of the First Breast Cancer Relapse: A Randomized Trial. Breast Cancer Research and Treatment. 81(1). 33–39. 13 indexed citations

16.

Kokko, R., K Holli, & Matti Hakama. (2002). Ca 15-3 in the follow-up of localised breast cancer. European Journal of Cancer. 38(9). 1189–1193. 58 indexed citations

17.

Kellokumpu‐Lehtinen, Pirkko, R. Kokko, Liisa Elomaa, et al.. (2002). Paclitaxel-ifosfamide for anthracycline-resistant advanced breast cancer.. PubMed. 22(2). 47–53. 2 indexed citations

18.

Saarenmaa, Irma, Tiina Salminen, Jorma Isola, et al.. (2001). The Visibility of Cancer on Previous Mammograms in Retrospective Review. Clinical Radiology. 56(1). 40–43. 16 indexed citations

19.

Saarenmaa, Irma, Tiina Salminen, J Isola, et al.. (2001). The effect of age and density of the breast on the sensitivity of breast cancer diagnostic by mammography and ultasonography. Breast Cancer Research and Treatment. 67(2). 117–123. 95 indexed citations

20.

Saarenmaa, Irma, Tiina Salminen, Jorma Isola, et al.. (2001). Validity of radiological examinations of patients with breast cancer in different age groups in a population based study. The Breast. 10(1). 78–81. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact